---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Daunorubicin Hydrochloride and Cytarabine Liposome - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/daunorubicinhydrochlorideandcytarabineliposome
version: v1
---

# Daunorubicin Hydrochloride and Cytarabine Liposome - NCI

# Daunorubicin Hydrochloride and Cytarabine Liposome

Placeholder slot

(DAW-noh-ROO-bih-sin HY-droh-KLOR-ide â€¦ sy-TAYR-uh-been LY-poh-some)

This page contains brief information about daunorubicin hydrochloride and cytarabine liposome
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Vyxeos

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8&audience=consumer)

## Use in Cancer

Daunorubicin hydrochloride and cytarabine liposome
is approved to treat:

- **[Acute myeloid leukemia](/Common/PopUps/popDefinition.aspx?id=46347&version=Patient&language=English)** (AML) that is newly [diagnosed](/Common/PopUps/popDefinition.aspx?id=46450&version=Patient&language=English). It is used in adults with therapy-related AML (tAML) or AML with [myelodysplasia](/Common/PopUps/popDefinition.aspx?id=45953&version=Patient&language=English)-related changes (AML-MRC).

Daunorubicin hydrochloride and cytarabine liposome is a [combination](/Common/PopUps/popDefinition.aspx?id=45650&version=Patient&language=English) form of [daunorubicin hydrochloride](/Common/PopUps/popDefinition.aspx?id=583859&version=Patient&language=English) and [cytarabine](/Common/PopUps/popDefinition.aspx?id=45155&version=Patient&language=English) contained inside [liposomes](/Common/PopUps/popDefinition.aspx?id=615392&version=Patient&language=English) (very tiny particles of fat). This form may work better than other forms of these drugs and have fewer [side effects](/Common/PopUps/popDefinition.aspx?id=46580&version=Patient&language=English). Also, because its effects last longer in the body, it doesn't need to be given as often. For more information about daunorubicin hydrochloride and [cytarabine](/Common/PopUps/popDefinition.aspx?id=45155&version=Patient&language=English) that may apply to this combination drug, see the Drug Information Summaries for [Daunorubicin Hydrochloride](/about-cancer/treatment/drugs/daunorubicinhydrochloride) and [Cytarabine](/about-cancer/treatment/drugs/cytarabine).

Daunorubicin hydrochloride and cytarabine liposome
is also being studied in the treatment of other types of
[cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=Patient&language=English).

## More About Daunorubicin Hydrochloride and Cytarabine Liposome

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/554979) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Daunorubicin Hydrochloride and Cytarabine Liposome](https://medlineplus.gov/druginfo/meds/a617045.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Clinical Trials Accepting Patients

[Find Clinical Trials for Liposome-encapsulated Daunorubicin-cytarabine](https://www.cancer.gov/research/participate/clinical-trials/intervention/C67504) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
